• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Goodbye Nasonex: Nasacort OTC here

Quote

Anonymous

Guest
B reps take another blow! Insomnia.....gonzo! Nasacort AQ gets FDA approval for OTC.....so long Nasonex! At least we have Dulera with no COPD indication to save our jobs!
 








Anonymous said:
B reps take another blow! Insomnia.....gonzo! Nasacort AQ gets FDA approval for OTC.....so long Nasonex! At least we have Dulera with no COPD indication to save our jobs!
Click to expand...

The asthma market is way bigger than the COPD market. You're griping about the lack of a COPD indication for Dulera...shows how ignorant you are...Go back to selling Dulera for appropriate patients with asthma and hopefully you will grow market share.
 




Anonymous said:
The asthma market is way bigger than the COPD market. You're griping about the lack of a COPD indication for Dulera...shows how ignorant you are...Go back to selling Dulera for appropriate patients with asthma and hopefully you will grow market share.
Click to expand...

You have proved that you are ignorant and stupid! The asthma market is bigger because of Pediatrics. What is the age indication for Dulera again?

COPD is also a growing market, that's why so many companies are investing in therapies for COPD. But they must be ignorant too right?

Dulera has been a disaster and will never replace any significant amount of revenue loss. Wow, look at that brains around here!
 




Top Bottom
Back
Quote